Primary oligomenorrhea
Methodology & AI Transparency ⓘ
Primary oligomenorrhea Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Primary oligomenorrhea (N91.3; PCOS, Endometriosis & Gynecologic Health) utilize iron repletion [Primary oligomenorrhea N91.3] and objective CBC & Serum in Primary oligomenorrhea (N91.3: Ferritin (heavy bleeding)) targets (Ferritin > 50 ng/mL (N91.3)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to PCOS, Endometriosis & Gynecologic Health under ICD-10-CM N91.3 for Primary oligomenorrhea clinical workups.
- 3 Typical cash cost range: Differential triage of Primary oligomenorrhea (N91.3) utilizes iron repletion [Primary oligomenorrhea N91.3].
- 4 Top reported side effects / signs: Longitudinal Primary oligomenorrhea monitoring tracks CBC & Serum in Primary oligomenorrhea (N91.3: Ferritin (heavy bleeding)) toward Ferritin > 50 ng/mL (N91.3).
Ask our AI Specialists anything about Primary oligomenorrhea
What Is Primary oligomenorrhea?
Physicians managing Primary oligomenorrhea (N91.3; PCOS, Endometriosis & Gynecologic Health) utilize iron repletion [Primary oligomenorrhea N91.3] and objective CBC & Serum in Primary oligomenorrhea (N91.3: Ferritin (heavy bleeding)) targets (Ferritin > 50 ng/mL (N91.3)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
In Primary oligomenorrhea (N91.3), physiological disruption stems from reduced hepatic SHBG in Primary oligomenorrhea (N91.3: (in PCOS)), informing PCOS, Endometriosis & Gynecologic Health protocols that track LH, FSH & in Primary oligomenorrhea (N91.3: Prolactin) (Normal ovulatory endocrine axis (N91.3)).
Common Symptoms & Clinical Signs
- • Presentation of Primary oligomenorrhea (N91.3): hyperandrogenic acne along in Primary oligomenorrhea (N91.3: the jawline, hirsutism,)
- • Secondary Primary oligomenorrhea clinical sign: pelvic pressure, bloating, in Primary oligomenorrhea (N91.3: or pain radiating)
- • Symptom flares in Primary oligomenorrhea correlating with CBC & Serum in Primary oligomenorrhea (N91.3: Ferritin (heavy bleeding)) deviation outside Ferritin > 50 ng/mL (N91.3)
- • Functional ob/gyn & pcos impact requiring iron repletion [Primary oligomenorrhea N91.3] evaluation (N91.3)
Primary oligomenorrhea Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N91.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | PCOS, Endometriosis & Gynecologic Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: CBC & Serum in Primary oligomenorrhea (N91.3: Ferritin (heavy bleeding)) | Ferritin > 50 ng/mL (N91.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: LH, FSH & in Primary oligomenorrhea (N91.3: Prolactin) | Normal ovulatory endocrine axis (N91.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Free & Total in Primary oligomenorrhea (N91.3: Testosterone + SHBG) | Sex-specific physiological range (N91.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Primary oligomenorrhea
Treatment selection for Primary oligomenorrhea depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Primary oligomenorrhea)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| 7 Questions to Bring to Your Next Doctor Visit (And Why They Work) Patients who bring a simple written list of 5 to 7 focused questions get clearer answers, leave with fewer medication mix-ups, and feel far more confident about their care plan—without making the appointment run longer. BMJ Quality & Safety / Patient Education and Counseling • 2026-11-01 • Systematic Review | N = 4,820 | 96/100 | PMID 34582101 ↗ |
| New Insights on Modeling Statin-Induced Reductions of heart and blood vessel Events in Primary: What a 6,735-Participant Study Found Our results show that, in individuals without clinical ASCVD, statin therapy has the potential to reduce the frequency of CV events. Cardiology • 2018-01-15 • Meta-Analysis | N = 6,735 | 94/100 | PMID 29705799 ↗ |
| New Insights on Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary: What a 628-Participant Study Found Ezetimibe plus atorvastatin was well tolerated, with a safety profile similar to atorvastatin alone and to placebo. Circulation • 2003-05-20 • Randomized Controlled Trial | N = 628 | 93/100 | PMID 12719279 ↗ |
| New Insights on Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in: What a 555-Participant Study Found Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Arthritis & rheumatology (Hoboken, N.J.) • 2021-01-15 • Phase III Randomized Trial | N = 555 | 93/100 | PMID 32770640 ↗ |
| New Insights on Responsiveness and thresholds for clinically meaningful changes in worst pain: What a 871-Participant Study Found Based on these results, clinically meaningful changes were defined as a reduction of 4 points for NRS-DYS and 2 points for NRS-NMPP. Fertility and sterility • 2021-02-15 • Phase III Randomized Trial | N = 871 | 93/100 | PMID 33066973 ↗ |
Primary oligomenorrhea Patient Community & “People Like Me” Threads
Filter Primary oligomenorrhea community threads and patient logs by age, biological sex, dosage, and treatment duration.